MerckMRK
Recorded

Merck 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 1 minParticipants18

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Welcome to the Merck & Co., Inc., Rahway, New Jersey, U.S.A., third quarter sales and earnings conference call. At this time, all participants are in a listen-only mode until the question and answer session of this conference. At that time, to ask a question, press star one on your phone and record your name at the prompt. This call is being recorded. If you have any objections, you may disconnect at this time. I would now like to turn the call over to Mr. Peter Dannenbaum, Senior Vice President, Investor Relations.

Peter DannenbaumSVP of Investor Relations

Sir, you may begin. Thank you, Julie, and good morning, everyone.

Peter DannenbaumSVP of Investor Relations

Welcome to the third quarter 2026 conference call for Merck & Company Incorporated, Rahway, New Jersey, U.S.A. Speaking on today's call will be Rob Davis, Chairman and Chief Executive Officer, Caroline Litchfield, Chief Financial Officer, and Dr. Dean Li, President of Research Labs. Before we get started, I'd like to point out that we have items in our GAAP results, such as acquisition-related charges, restructuring costs, and certain other items that we have excluded from our non-GAAP results. There is a reconciliation in our press release. I will also remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the Safe Harbor provision of the U.S. Private Securities Litigation Reform Act of 1995.

Peter DannenbaumSVP of Investor Relations

Such statements are made based on the current beliefs of our company's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A in the 2025 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck & Company Incorporated, Rahway, New Jersey, U.S.A., undertakes no obligation to publicly update any forward-looking statements. During today's call, a slide presentation will accompany our speakers' prepared remarks. These slides, along with the earnings release, today's prepared remarks, and our SEC filings, are all posted to the investor relations section of our company's website. With that, I'd like to turn the call over to Rob.

Rob DavisChairman and CEO

Thank you, Peter. Good morning, and thank you for joining today's call. 2026 continues to be a year of substantial progress for our company. We're executing well on all fronts, demonstrated particularly by the many new product launches now successfully underway and the important clinical milestones we're achieving that are further de-risking the substantial long-term opportunity of our late-phase pipeline. This momentum extends across multiple therapeutic areas and modalities, and there is much more to come, with numerous significant readouts still to occur over the coming years. I'm very pleased that the disciplined execution of our strategy over the past several years is increasingly translating into meaningful clinical, regulatory, and commercial results. The breadth of these achievements strengthens my confidence in the future of our company and our ability to deliver long-term value for patients and shareholders.

Rob DavisChairman and CEO

Turning to our third quarter results, we delivered solid performance with revenue of $18.1 billion, reflecting increased contributions from new products as well as strength in oncology and animal health. Caroline Litchfield will discuss our results and the full-year outlook in greater detail in a moment. We also achieved several important clinical and regulatory milestones. In oncology, last weekend's ESMO meeting showcased potential practice-changing advances for several innovative programs, highlighted by the first positive phase III results from our expansive global TroFuse program for sac-TMT in advanced or recurrent endometrial cancer. Additional data shared at the meeting from our partner Kelun-Biotech further support the potential of sac-TMT in lung cancer and other tumor types. We are encouraged by the landmark validation of a therapeutic cancer vaccine with positive phase III data presented for intismeran autogene as an adjuvant treatment for certain patients with melanoma.

Rob DavisChairman and CEO

This new approach may offer a tangible opportunity to change the trajectory of a patient's cancer. In ophthalmology, we presented results from the BRUNELLO study evaluating remigromig in diabetic macular edema, a significant milestone for our rapidly advancing retinal disease portfolio. Finally, in immunology, we presented encouraging phase IIb results in HS and look forward to advancing our TL1A development program. This year's clinical and commercial progress underlines the ongoing transformation of our business and provides us with greater visibility into the trajectory of our emerging and expansive new product portfolio. The opportunity we have to drive strong long-term growth beyond the KEYTRUDA LOE period is becoming increasingly clear as we achieve these scientific and commercial milestones. As we look ahead, we will remain focused on successfully executing our launches, broadening and advancing our pipeline, and making meaningful investments to realize the full potential of these opportunities.

Rob DavisChairman and CEO

I want to recognize and thank our dedicated global teams for their ongoing commitment to delivering value for patients, shareholders, and all of our stakeholders. Now I will turn the call over to Caroline Litchfield.

Caroline LitchfieldCFO

Thank you, Rob Davis. Good morning. As Rob Davis noted, we delivered solid performance in the quarter, driven by increasing contributions from our compelling array of important new products and continued strength in oncology and animal health. Strong commercial and operational execution continues to propel our near-term performance while we invest to optimize our launches and advance our broad and deep pipeline to create long-term value for patients, customers, and shareholders. Now turning to our third quarter results.

Caroline LitchfieldCFO

Total company revenues were $18.1 billion, an increase of 5%, or 4% excluding the impact of foreign exchange. The following revenue comments will be on an ex-exchange basis. In oncology, sales of the KEYTRUDA family of products, which includes KEYTRUDA and KEYTRUDA QLEX, increased 6% to $8.6 billion, with global growth driven by strong uptake in earlier stage cancers and continued robust demand for metastatic indications. Key contributors to growth included strong utilization in tumors that primarily affect women, particularly cervical and breast cancers, as well as increased use of KEYTRUDA plus PADCEV in urothelial cancer. We also saw continued uptake in earlier stage head and neck cancer. As expected, the timing of U.S. customer purchases last year created a headwind to growth, but this was largely offset by an increase in channel inventory, which we expect to unwind in the fourth quarter. Sales of KEYTRUDA QLEX were $830 million.

Caroline LitchfieldCFO

We continue to see adoption increase, which supports our confidence in the trajectory of the product. In our broader oncology portfolio, WELIREG sales increased 58% to $307 million, driven by increased use in previously treated patients and as adjuvant treatment for certain patients with renal cell carcinoma in the U.S., as well as continued uptake from ongoing launches in international markets. In vaccines and infectious diseases, GARDASIL sales were $2 billion, an increase of 14%. In the U.S., sales grew 18%, benefiting from a significant CDC purchase and price, while international markets increased 6%. In pneumococcal, CAPVAXIVE sales were $263 million, an increase of 7%, driven by ongoing launches in certain international markets. In the U.S., sales declined 13% as increased market share was more than offset by lower adult pneumococcal vaccination rates. In RSV, ENFLONSIA sales of $187 million reflect seasonal demand and associated inventory build.

Caroline LitchfieldCFO

In cardiometabolic and respiratory, WINREVAIR continued its momentum with global sales of $694 million, an increase of 94%, reflecting strong demand from adults with pulmonary arterial hypertension, as well as a benefit from channel inventory. In the U.S., nearly 1,600 new patients received a prescription, approximately 30% of whom were on background therapies that did not include a prostacyclin. Outside the U.S., we continue to progress with ongoing launches. OHTUVAYRE sales were $184 million, reflecting continued demand from adults with COPD, partially offset by a small headwind from the timing of specialty pharmacy purchases. While early, we are encouraged by the initial launch of LIPFENDRA. Prescription trends and physician feedback has been positive. Additionally, we have established programs to support access and affordability for eligible patients.

Caroline LitchfieldCFO

As expected, broad access will take time to build, and we remain confident in the long-term opportunity for this important treatment option for adults with elevated LDL cholesterol. Our animal health business delivered growth of 3%. Companion animal sales increased 6%, driven by new product launches. Livestock sales grew 2% due to higher demand for poultry products. I will now walk you through the remainder of our P&L, and my comments will be on a non-GAAP basis. Gross margin decreased slightly to 81.4%. Operating expenses increased 12% to $7.4 billion, reflecting increased investments to support our launches and advance our diverse early and late-phase pipeline. This increase was partially offset by benefits from our ongoing multi-year optimization effort and the recognition of a portion of the external funding for sac-TMT development.

Caroline LitchfieldCFO

There was also a $400 million upfront charge related to the license agreement with SciBrunch, compared with a $300 million business development charge a year ago. Other expense increased to $420 million, primarily reflecting financing costs related to recent business development transactions. Our tax rate was 10.9%, reflecting a benefit from certain discrete items. Taken together, earnings per share were $2.49, which includes a charge of $0.12 per share related to the SciBrunch license agreement. Now turning to our 2026 non-GAAP guidance. We have narrowed the range and raised the midpoint of both our full-year revenue and EPS guidance. We now expect revenue to be between $66.8 billion and $67.3 billion, representing growth of 3%-4%, including a positive impact from foreign exchange of approximately one percentage point using mid-October rates. Our gross margin assumption remains approximately 81%. Operating expenses are expected to be between $42.4 billion and $42.9 billion.

Caroline LitchfieldCFO

Other expense is still expected to be approximately $1.4 billion. We now expect a full year tax rate between 32% and 33%. We assume approximately 2.48 billion shares outstanding. Taken together, we expect EPS of $2.77-$2.82, including a positive impact from foreign exchange of approximately $0.15 using mid-October rates. This range also includes the SciBrunch charge. As you consider your models, there are a few items to keep in mind. Third quarter sales benefited by approximately $550 million from favorable purchase timing in the U.S. We expect that the benefit related to KEYTRUDA and WINREVAIR to fully unwind in the fourth quarter, while the majority of the benefit to vaccines, primarily related to GARDASIL, is expected to unwind next year. As we look forward to 2027, we recently noted an expectation for modest revenue growth.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day